The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.
An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.
US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.
Roche unit Spark Therapeutics is pursuing a “misguided” lawsuit that contravenes its stated mission to combat systemic racism, according to gene therapy developer Bluebird Bio.
Poland’s largest pharmaceutical company has asked the federal court to let it pursue arbitration in a Swiss court for a trade secrets dispute between India’s Rubicon Research and North Carolina biotech firm Kartha Pharmaceuticals.
Masimo wants to bar Apple from selling the Apple Watch Series 6, alleging the mobile manufacturer infringed five of its blood pressure monitoring patents.
Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.
The UK Government has failed to convince UK Supreme Court judges that Servier Laboratories misrepresented its blood pressure drugs patent in legal proceedings to block generic competitors from entering the market.
The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.